HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

Brussels, Belgium, {27 April 2004} Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has issued a positive decision for VELCADE, a new treatment for multiple myeloma, a form of blood cancer. The novel drug is indicated to treat multiple myeloma patients who have received at least two prior therapies and demonstrated disease progression on their last therapy.

VELCADE is a completely new approach to treating multiple myeloma that acts on a unique target in cells called the proteasome.

Multiple myeloma is the second most common blood cancer, representing approximately one percent of all cancers and two percent of all cancer deaths. Worldwide in 2000, there were 73,943 cases of multiple myeloma and 57,370 deaths. In Europe there were approximately 19,000 cases in 2000 and just under 15,000 deaths (1). Only 30 percent of multiple myeloma patients survive longer than five years (2).

"The approval of VELCADE by the European Agency for the Evaluation of Medicinal Products (EMEA) represents a breakthrough in our continued battle against multiple myeloma" said Professor Mario Boccadoro, Professor of Hematology, Director of the Section of Hematology, University of Torino, Italy. "With its new and unique mechanism of action, VELCADE represents a new treatment option for patients".

Clinical results from a phase II study have shown that VELCADE can slow, reverse or halt progression of disease in patients who failed on two or more treatments, potentially helping patients live longer. In a study of 202 patients with relapsed and refractory multiple myeloma and who progressed after initial treatments, 35% responded to VELCADE and 10% had a complete remission. This pivotal study was the basis for an accelerated review of VELCADE by U.S. Food and Drug Administration (FDA) and approval within four months of the New Drug Application submission on 13 May 2003.

"We are deli
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are ... announced its new collection of power suppliers. Additionally, it ... power suppliers. All the new models come with big ... until Dec. 20, 2014. , SWAccessControl.com has thousands of ... it for a long time. It is very wise ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 “BlackVue” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... unique and powerful options in the car camera industry. ... and it can be hard to find the one ...
(Date:11/23/2014)... November 23, 2014 BambooFlooringChina.com , the ... click strand woven bamboo flooring collection. Now, the ... to the company’s CEO, the promotion is valid until Dec. ... comes with a smooth and dust-free surface, which makes it ... in the industry, the company wants to make its website ...
(Date:11/22/2014)... 23, 2014 Cancer researchers in New ... between intercellular communication tunnels and the growth and spread ... story on the Surviving Mesothelioma website. , ... University of Minnesota have just released their study on ... materials between cells. They found that mesothelioma cells ...
(Date:11/22/2014)... 23, 2014 Recently, Locks-Magnetic.com , ... a new promotion of mag locks for glass doors ... attracting discount on these fresh products. Customers can get ... for glass doors are in excellent performance. Customers who ... website as soon as possible. They also can ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2
(Date:11/21/2014)... 2014  Market research firm Kalorama information says that ... Buy, in the medical device industry.  The firm thinks ... produce just 3% growth this year, which led firms ... product lines and entrance by acquisition into new competitive ... devices, The Global Market for Medical Devices, 5 ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014  The ... at the 2014 AAGL Global Congress demonstrates continued ... insert designed to provide bowel control. One of the ... Associate Professor and Division Chief of Urogynecology and ... Carolina, won an Award for Best Written Abstract ...
(Date:11/21/2014)... HILLS, Calif. , Nov. 20, 2014 Oxis ... Ken Eaton , the election of Anthony J. Cataldo ... as President. Effective November 19, 2014, Ken ... member of the Board of Directors of Oxis International, Inc. ... Cataldo has been named Chief Executive Officer of Oxis ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3
Cached News: